Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 May 15;40(5):633-5.
doi: 10.1016/j.immuni.2014.05.001.

p53 keeps bystanders at the gates

Affiliations
Comment

p53 keeps bystanders at the gates

Michael A Fray et al. Immunity. .

Abstract

The inappropriate expansion of self-reactive "bystander" T cells can contribute to autoimmune disease. In this issue of Immunity, Watanabe et al. (2014) demonstrate that the tumor suppressor p53 prevents the cytokine-dependent proliferation of T cells in the absence of cognate antigens.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. The Tumor Suppressor p53 Blocks Bystander T Cell Proliferation Triggered by IL-2
(upper left) In response to a pathogenic challenge, CD4+ T cells that are not specific for antigen are exposed to mitogenic cytokines such as IL-2. In normal animals, IL-2-dependent signals increase the abundance of p53 protein, blocking the proliferation of these “bystander” T cells. (upper right) T cells that lack functional p53 proliferate when exposed to IL-2, even in the absence of TCR signaling, confirming the essential role of p53 in the enforcement of this checkpoint. (bottom right) The specific recognition of antigen (pMHC) by the TCR increases the concentration of the mRNA encoding Mdm2, a ubiquitin ligase that targets p53 for proteasomal degradation. The ensuing degradation of p53 enables the expansion of antigen-specific T cell clones while ensuring that potentially self-reactive “bystander” cells do not participate in the immune response.

Comment on

Similar articles

Cited by

References

    1. den Braber I, Mugwagwa T, Vrisekoop N, Westera L, Mögling R, de Boer AB, Willems N, Schrijver EHR, Spierenburg G, Gaiser K, et al. (2012). Immunity 36, 288–297. - PubMed
    1. Green DR, and Kroemer G. (2009). Nature 458, 1127–1130. - PMC - PubMed
    1. Guidos CJ, Williams CJ, Grandal I, Knowles G, Huang MT, and Danska JS (1996). Genes Dev. 10, 2038–2054. - PubMed
    1. Haks MC, Krimpenfort P, van den Brakel JH, and Kruisbeek AM (1999). Immunity 11, 91–101. - PubMed
    1. Kawashima H, Takatori H, Suzuki K, Iwata A, Yokota M, Suto A, Minamino T, Hirose K, and Nakajima H. (2013). J. Immunol 191, 3614–3623. - PubMed

MeSH terms